Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Semax and BPC-157 — mechanism, side effects, legal status, and pricing.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10) with a Pro-Gly-Pro C-terminal extension for metabolic stability. It was developed at the Institute of Molecular Genetics (Russian Academy of Sciences) and registered as a drug in Russia in 1994. It is not FDA-approved.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
Semax
BPC-157
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Semax
BPC-157
COA corpus from Disclosed Labs — independently tested batches only.
Semax
82
COAs
99.5%
Avg purity
16
Labs
BPC-157
334
COAs
99.3%
Avg purity
16
Labs
BPC-157 is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Semax remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Semax's evidence base is primarily Russian-language clinical literature. Gusev, Skvortsova and colleagues reported improved neurological recovery in acute hemispheric ischemic stroke when Semax was added to conventional therapy (Zh Nevrol Psikhiatr, 1997; PMID 11517472), and subsequent Russian studies extended use to cerebrovascular insufficiency (PMID 15792140). Preclinical work by Dolotov, Myasoedov and colleagues demonstrated that intranasal Semax rapidly elevates BDNF protein and TrkB activation in rat hippocampus and basal forebrain (Brain Res 2006, PMID 16996037; J Neurochem 2006, PMID 16635254). Genome-wide transcriptional analysis by Medvedeva et al. in rat focal ischemia showed Semax modulates a broad panel of immune-response and vascular-system genes (BMC Genomics 2014, PMID 24661604). Western evidence is limited; Semax has not been evaluated by the FDA and has no pivotal trials in the US or EU.
Key references
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Semax (Cognitive) and BPC-157 (Recovery) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs